• About us
• Contact

Advertisement

Document › Details

CureVac AG. (2/19/19). "Press Release: CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference". Tübingen & Boston, MA.

	Region	New York, NY
	Country	United States (USA)
	Organisation	CureVac AG
	Today	CureVac SE
	Group	CureVac (Group)
	Organisation 2	SVB Leerink LLC
	Today	Leerink Partners (Group)
	Group	Leerink Partners (Group)
	Product	SVB Leerink Annual Global Healthcare Conference 2019 New York
	Product 2	mRNA-based drug
	Index term	CureVac–SVB: investor conference, 201902 supply service CureVac presents at SVB Leerink Global Healthcare Conference in NYC
	Person	Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia)

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 8th Annual Leerink Partners Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 1:50 p.m. ET.

A live broadcast of the presentation will be available at www.curevac.com/en/newsroom/curevacevents. An archived replay of the presentation will be available on the company’s website for approximately 3 months following the presentation.

Record changed: 2023-06-05

Advertisement

More documents for CureVac (Group)

• [1] CureVac N.V.. (4/24/24). "Press Release: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer". Tübingen & Boston, MA....
• [2] CureVac N.V.. (4/16/24). "Press Release: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines". Tübingen & Houston, TX....
• [3] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
• [4] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
• [5] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
• [6] CureVac N.V.. (9/28/23). "Press Release: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany". Tübingen & Boston, MA....
• [7] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
• [8] LimmaTech Biologics AG. (7/20/23). "Press Release: LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth". Schlieren....
• [9] CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA....
• [10] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.